share_log

uniQure CompletesEnrollment In First Cohort Of Phase I/II Clinical Trial Of AMT-130 For The Treatment Of Huntington's Disease

uniQure CompletesEnrollment In First Cohort Of Phase I/II Clinical Trial Of AMT-130 For The Treatment Of Huntington's Disease

UnQure完成AMT-130治疗亨廷顿病I/II期临床试验的第一队列研究
Benzinga Real-time News ·  2021/04/05 19:09

uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of patient enrollment in the first dose cohort of a randomized, double-blinded, Phase I/II clinical trial of AMT-130 for the treatment of early stage Huntington's disease. The Company also announced plans to begin an open-label clinical trial of AMT-130 in Europe later this year.

亚洲网加利福尼亚州圣何塞2月16日电领先的基因治疗公司UnQure N.V.(纳斯达克市场代码:Qure)今天宣布,AMT-130治疗早期亨廷顿病的随机、双盲、I/II期临床试验的第一剂患者招募工作已经完成。UnQure N.V.是一家为有严重医疗需求的患者推进变革性疗法的领先基因治疗公司。该公司还宣布计划今年晚些时候在欧洲开始AMT-130的开放标签临床试验。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发